Parkman Healthcare Partners’s Edwards Lifesciences EW Stock Holding History

Parkman Healthcare Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.4M	Buy	167,155 +16,170	+11%	+$1.33M	1.38%	24
2025 Q4	$12.9M	Sell	150,985 -4,781	-3%	-$392K	1.23%	29
2025 Q3	$12.1M	Sell	155,766 -95,975	-38%	-$7.5M	1.26%	28
2025 Q2	$19.7M	Buy	251,741 +50,922	+25%	+$3.8M	2.26%	14
2025 Q1	$14.6M	Buy	200,819 +55,605	+38%	+$3.98M	1.73%	22
2024 Q4	$10.8M	Buy	+145,214	New	+$10.2M	1.43%	25
2023 Q4	–	Sell	-40,000	Closed	-$2.77M	–	97
2023 Q3	$2.77M	Buy	+40,000	New	+$3.21M	0.51%	59
2023 Q1	–	Sell	-54,579	Closed	-$4.07M	–	87
2022 Q4	$4.07M	Sell	54,579 -27,327	-33%	-$2.11M	1.08%	38
2022 Q3	$6.77M	Buy	+81,906	New	+$7.88M	1.92%	18
2021 Q1	–	Sell	-50,584	Closed	-$4.62M	–	89
2020 Q4	$4.62M	Sell	50,584 -71,947	-59%	-$5.97M	1.18%	33
2020 Q3	$9.78M	Buy	122,531 +2,531	+2%	+$197K	2.59%	8
2020 Q2	$8.29M	Buy	+120,000	New	+$8.53M	2.34%	12

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Parkman Healthcare Partners's EW Position: Q1 2026 in Review

Parkman Healthcare Partners increased its Edwards Lifesciences (EW) stake by 11% in Q1 2026, buying an estimated $1.33M and bringing the position to 167,155 shares worth $13.4M. The position accounts for 1.38% of the portfolio, ranked #24.

Parkman Healthcare Partners first reported a position in EW in Q2 2020 and has held it in 12 quarters since. The position peaked at $19.7M in Q2 2025. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Parkman Healthcare Partners held 167,155 shares of Edwards Lifesciences worth $13.4M as of Q1 2026.
Parkman Healthcare Partners bought 16,170 Edwards Lifesciences shares in Q1 2026, an estimated $1.33M.
Edwards Lifesciences made up 1.38% of Parkman Healthcare Partners's portfolio in Q1 2026, its #24 holding.
Parkman Healthcare Partners first reported a position in Edwards Lifesciences in Q2 2020 and has held it in 12 quarters since.
Parkman Healthcare Partners's Edwards Lifesciences position peaked at $19.7M in Q2 2025.
1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.